{"created":"2023-07-27T06:56:42.558494+00:00","id":53610,"links":{},"metadata":{"_buckets":{"deposit":"7723fc5f-375c-4cc8-917e-1bf2e58b0613"},"_deposit":{"created_by":18,"id":"53610","owners":[18],"pid":{"revision_id":0,"type":"depid","value":"53610"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00053610","sets":["2812:2813:2821"]},"author_link":["24844","95244"],"item_9_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2013-05-22","bibliographicIssueDateType":"Issued"},"bibliographicPageStart":"4p.","bibliographicVolumeNumber":"2011 – 2012","bibliographic_titles":[{"bibliographic_title":"平成24(2012)年度 科学研究費補助金 若手研究(B) 研究成果報告書"},{"bibliographic_title":"2012 Fiscal Year Final Research Report","bibliographic_titleLang":"en"}]}]},"item_9_creator_33":{"attribute_name":"著者別表示","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Mori, Noriko"}],"nameIdentifiers":[{"nameIdentifier":"24844","nameIdentifierScheme":"WEKO"},{"nameIdentifier":"30579660","nameIdentifierScheme":"e-Rad","nameIdentifierURI":"https://kaken.nii.ac.jp/ja/search/?qm=30579660"},{"nameIdentifier":"30579660","nameIdentifierScheme":"研究者番号","nameIdentifierURI":"https://nrid.nii.ac.jp/nrid/1000030579660"}]}]},"item_9_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"子宮内膜癌検体の免疫組織染色法で、HER2発現は、p-AKT発現とは相関が認められなかったが、p-mTOR発現と負の相関が認められ、優位な予後不良因子であった。子宮内膜癌細胞株でHER2を抑制すると、p-AKT の発現低下とMPAや抗癌剤への軽度の感受性増強を認めた。抗HER2モノクローナル抗体のTrastuzumabは、低用量PTXの感受性増強に効果が認められ、HER2をターゲットとした分子標的薬の有効性を推測できた。","subitem_description_type":"Abstract"},{"subitem_description":"Immunohistochemical analysis using surgical specimens of endometrial cancers showed a negative correlation between HER2 expression and phosphorylated (p)-mTOR but not p-AKT. Kaplan-Meier analysis revealed that high HER-2 expression appeared to be a risk factor of survival rate. Short interfering RNA (siRNA)-based knockdown of HER-2 reduced p-AKT expression and slightly increased sensitivity to MPA and paclitaxel (PTX) in endometrial cancer cells. Trastuzumab, anti-HER2 monoclonal antibody, enhanced sensitivity to low dose of PTX in endometrial cancer cells. This study suggested the efficacy of new HER2 targeted therapy for endometrial cancer.","subitem_description_type":"Abstract"}]},"item_9_description_22":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"研究課題/領域番号:23701097, 研究期間(年度):2011-2012","subitem_description_type":"Other"},{"subitem_description":"出典：研究課題「HER2をターゲットとした子宮内膜癌の新たな分子標的治療の開発」課題番号23701097\n（KAKEN：科学研究費助成事業データベース（国立情報学研究所））\n（https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-23701097/23701097seika/）を加工して作成","subitem_description_type":"Other"}]},"item_9_description_5":{"attribute_name":"提供者所属","attribute_value_mlt":[{"subitem_description":"金沢大学医薬保健研究域医学系","subitem_description_type":"Other"}]},"item_9_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.24517/00059892","subitem_identifier_reg_type":"JaLC"}]},"item_9_relation_28":{"attribute_name":"関連URI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/search/?qm=30579660"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/search/?qm=30579660","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23701097/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23701097/","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-23701097/23701097seika/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-23701097/23701097seika/","subitem_relation_type_select":"URI"}}]},"item_9_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"森, 紀子"}],"nameIdentifiers":[{"nameIdentifier":"95244","nameIdentifierScheme":"WEKO"},{"nameIdentifier":"30579660","nameIdentifierScheme":"e-Rad","nameIdentifierURI":"https://kaken.nii.ac.jp/ja/search/?qm=30579660"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-11-20"}],"displaytype":"detail","filename":"ME-PR-MORI-N-kaken 2013-4p.pdf","filesize":[{"value":"339.2 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"ME-PR-MORI-N-kaken 2013-4p.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/53610/files/ME-PR-MORI-N-kaken 2013-4p.pdf"},"version_id":"b56606e2-7c64-4f13-ada1-b2e95326656a"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"HER2をターゲットとした子宮内膜癌の新たな分子標的治療の開発","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"HER2をターゲットとした子宮内膜癌の新たな分子標的治療の開発"},{"subitem_title":"Development of HER2 targeted therapy for endometrial carcinoma","subitem_title_language":"en"}]},"item_type_id":"9","owner":"18","path":["2821"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-11-20"},"publish_date":"2020-11-20","publish_status":"0","recid":"53610","relation_version_is_last":true,"title":["HER2をターゲットとした子宮内膜癌の新たな分子標的治療の開発"],"weko_creator_id":"18","weko_shared_id":-1},"updated":"2024-07-01T05:55:26.347814+00:00"}